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1. Introduction
Today biotechnology and the process of genetic modification is emerging and advancing
worldwide. At the forefront of this technology is soybean, which has become a popular sub‐
ject of genetic modification due to its versatility and economical importance as a crop plant.
Over 15 years ago the first herbicide resistant soybeans were introduced into the market. By
1997, approximately 8% of all soybeans cultivated for commercial use in the United States
were genetically modified. This trend has grown exponentially and by 2011 the percentage
of genetically modified soybean rose to 94% in the United States and 81% worldwide. The
technology to genetically modify soybean has not only had a huge impact on the commer‐
cial agricultural market, but has paved the way to an onset of both traditional and nontradi‐
tional uses for soybean as well as opening up many new potential applications for this
important crop plant. Soybean has become a popular subject of genetic modification over
the past two decades and with the advancement of plant transformation technology, it is
now possible to manipulate and or add various traits to soybean.
2. Soybean transformation
There are several protocols used to genetically transform plants with either stable or transi‐
ent expression. Some of the methods include electroporation, silicon carbide fibers, liposome
mediated transformation and in planta Agrobacterium-mediated transformation via vacuum
infiltration of whole plant. However, many of these methods are not used for soybean trans‐
formation because of low transformation efficiencies. Two more commonly used platforms
© 2013 Hudson et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
that have been successfully optimized for stable soybean transformation include cotyledona‐
ry node–Agrobacterium-mediated transformation and somatic embryo–particle-bombard‐
ment-mediated transformation.
The Agrobacterium-mediated plant transformation method uses a soil dwelling bacteria spe‐
cies called Agrobacterium tumefaciens to transfer desirable genes into plants. Using this meth‐
od, a foreign gene can be placed within the T- DNA boarder regions of the bacterial plasmid
which then integrates into a host plant’s genome [1]. Wounded plant tissue gives off specific
phenolic compounds which induce Agrobacterium to express a set of virulence (vir) genes.
The expression of the vir genes results in the production of single-stranded DNA that is
transferred and integrated into the plant genome.
There are several advantages of Agrobacterium-meditated plant transformation including
straight forward methodology, minimal equipment cost, and reliable insertion of a single or
a low copy transgene number. The first reported transformation of soybean with an Agrobac‐
terium strain used co-cultivation followed by organogenesis from cotyledonary nodes [2].
This work was followed by using Agrobacterium mediated transformation of immature coty‐
ledons [3], and embryogenic suspension cultures [4]. Since then, several groups have
worked to improve these methods, in particular the transformation and regeneration from
cotyledonary nodes. Cotyledonary node regions contain axillary meristems at the junction
between cotyledon and hypocotyl. Generally, the cotyledonary nodes are pre-wounded and
then co-cultivated with Agrobacterium. The axillary meristems proliferate and regenerate
through the formation of multiple adventitious shoots on culture medium containing a cyto‐
kinin. In the United States, public facilities, including the Plant Transformation Facility at Io‐
wa State University and the Plant Transformation Core Facility at the University of
Missouri, provide fee for service genetic transformation of soybean for public research,
mainly by cotyledonary node Agrobacterium-mediated transformation.
The other widely used method of soybean transformation is somatic embryo particle bom‐
bardment-mediated transformation also called particle bombardment, or biolistic technolo‐
gy. This method directs small tungsten or gold particles coated with the desired genes
toward the target plant cells with enough force to penetrate the cell wall and membrane [5].
Once inside the cell the DNA disassociates from the particle and becomes integrated into the
plant genome.
The particle bombardment transformation method was first used in soybean in 1988 by
McCabe et al., who successfully transformed immature seed meristem [6] and was followed
by the transformation of somatic embryonic tissue [7], and apical meristem [8]. Transforma‐
tion of somatic embryos has been the most successful method and is induced from imma‐
ture cotyledons cultured on medium containing moderately high concentrations of an auxin.
These cotyledons are used to generate proliferative embryogenic cultures and to recover
whole plants. A major advantage of the particle bombardment transformation method rela‐
tive to Agrobacterium-based methods is the removal of biological incompatibilities between
tissues of many plant species and the Agrobacterium vector. However, it has been shown that
certain genotypes are more susceptible to the formation of proliferative embryogenic tissue
than others. Limitations of the bombardment process include the requirement of specialized
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equipment (gene gun), transformation limited to cells at or near the surface, and high copy
number events with high levels of recombination which may not be desirable.
The development of soybean transformation methods has paved the way for an extensive
amount of research to develop genetically modified soybeans that have been widely adopt‐
ed for crop improvement purposes. This has been a fast growing field with the addition of
many agronomic, nutraceutical, and pharmaceutical traits being developed, the progress of
which will be reviewed in this chapter.
3. Agronomical improvements in soybean
3.1. Herbicide tolerance
In 1970, glyphosate, a broad-spectrum foliar herbicide, was discovered [9]. Glyphosate in‐
hibits 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), a crucial enzyme of the shiki‐
mate biosynthetic pathway that is responsible for the production of several essential
aromatic amino acids. Glyphosate was commercially introduced in 1974 and by 1995 use
had reached 4. 5 million kg in the United States. Due to popularity and broad use of this
herbicide by farmers, glyphosate became a candidate for research in creating herbicide re‐
sistant soybeans and has led to one of the most well-known examples of herbicide tolerance:
The Roundup Ready® soybean developed by Monsanto. Roundup Ready® soybeans were
one of the first examples of a commercially viable transgenic plant. These transgenic soy‐
beans express functional EPSPS providing tolerance to the herbicide glyphosate (Round‐
upTM). The popularity of these soybeans grew with farmers since RoundupTM could be
applied to a field of Roundup Ready® soybeans to significantly reduce weed populations
while leaving the soybean crop unharmed. The development of Roundup Ready® soybeans
offered farmers many advantages in a system that was relatively easy to use. The level and
consistency of weed control allowed farmers to take advantage of a no-till system, and elim‐
inated the need for cultivation allowing growers to space rows more closely. Narrow row
planting results in higher yields due to a more efficient use of space and may result in better
weed control, as the canopy closes more quickly providing earlier competition against
weeds. In addition, the window of application for RoundupTM is wider than for other post
emergence herbicides currently used in soybeans, both in terms of the stage of soybean
growth and the ability to achieve effective control of larger weeds. These factors contributed
to the popularity of this weed control technology. At present, approximately 90% of the soy‐
beans farmed in the United States utilize this technology.
In response to Monsanto's hugely successful Roundup Ready® crops, Bayer Crop Science re‐
leased its own herbicide tolerant soybean known as Liberty Link® soybean [10]. Liberty
Link® soybeans were developed to express a gene derived from the bacteria Streptomyces vir‐
idochromogenes called phosphinothricin-N-acetyltransferase (PAT). PAT is a glutamine syn‐
thetase inhibitor that binds to glutamate, making plants resistant to the broad-spectrum
contact herbicide glufosinate ammonium. This herbicide causes cessation of photosynthesis
and plant death by interfering with the biosynthetic pathway of the amino acid glutamine
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and with ammonia detoxification. Glufosinate ammonium is the active ingredient in phos‐
phinothricin herbicides (Basta®, Ignite®, Rely®, Liberty®, Harvest®, and Finale®) used to con‐
trol a wide range of weeds after the crop emerges or for total vegetation control on land not
used for cultivation. Since glufosinate ammonium-based herbicides function by a different
mode of action than glyphosate-based herbicides, the Liberty Link® system provides farmers
with an alternative strategy for controlling weeds.
There are several other examples of transgenic soybeans expressing herbicide resistance
traits that are in various stages of development. Pioneer has developed a transgenic soybean
product that provides tolerance to two different classes of herbicides: glyphosate and aceto‐
lactate synthase (ALS)-inhibiting herbicides. These soybean plants express the glyphosate
acetyltransferase (GAT4601) and modified version of a soybean acetolactate synthase (GM-
HRA) proteins. [11]. The GAT4601 protein confers tolerance to glyphosate-containing herbi‐
cides by acetylating glyphosate and thereby rendering it non-phytotoxic. The GM-HRA
protein confers tolerance to the ALS-inhibiting class of herbicides. The development of GM
soybeans with characteristics controlled by multiple genes leading to the expression of two
herbicides is a different approach than previous strategies involving single characteristics
controlled by a single gene. These genetically modified soybeans express a combination of
herbicides with different modes of action. Inherent crop tolerance will enable more effective
management of weed populations.
BASF has used a similar method to introduce a soybean that combines herbicide-tolerant
soybean varieties with the broad spectrum imidazolinone class of herbicides. These trans‐
genic soybeans contain the csr1-2 gene derived from Arabidopsis thaliana that encodes the
imidazolinone-tolerant AHAS-Large subunit (also known as ALS). The AHAS-L subunit in‐
teracts with the endogenous soybean small regulatory subunit to form an enzyme complex
that catalyzes the first step in the synthesis of branched-chain essential amino acids, valine,
leucine, and isoleucine [12]. The AHAS enzymes occur ubiquitously in plants. Imidazoli‐
none herbicides inhibit the native enzymes, resulting in plant death.
To address the potential emergence of other herbicide resistant broadleaf weeds, Monsanto
has developed a line of transgenic soybeans that are resistant to treatment with dicamba
[13]. Dicamba (3,6-dichloro-2-methoxybenzoic acid) is a low-cost, widely-used, broad leaf
herbicide that is environmentally friendly. Soybeans transformed with a genetically engi‐
neered bacterial dicambamonooxygenase (DMO) gene were able to inactivate dicamba,
making them resistant to this herbicide. Dicamba-resistant soybeans are in the advanced
stages of research and development and are predicted to be commercialized soon.
Syngenta and Bayer CropScience are co-developing HPPD-inhibitor tolerant soybeans, a
novel herbicide tolerance trait for soy. The event consists of a molecular stack of a gene con‐
ferring tolerance to hydroxyphenylpyruvatedioxygenase (HPPD)-inhibiting herbicides as
well as a gene for glufosinate tolerance. Inhibition of HPPD stops the catabolic degradation
of tyrosine to plastoquinones which is important for photosynthesis, carotenoid biosynthe‐
sis, and tocopherol production [14]. This multiple herbicide tolerance stack will enable the
use of multiple herbicides and will be an important new tool for soybean growers faced
with increasing pressure from resistant weeds. In the future, other innovative molecular
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strategies can be expected to generate genetically modified (GM) soybeans with novel fea‐
tures to combat weeds and enhance weed resistance. These new GM soybeans will reduce
environmental contamination risks and reduce costs for consumers and producers.
3.2. Insect resistance
Insect pest management through the use of chemicals has brought about considerable pro‐
tection to crop yields over the past several decades. Unfortunately, extensive and indiscrimi‐
nate usage of chemical pesticides has resulted in environmental degradation, adverse effects
on human health and other organisms, eradication of beneficial insects, and development of
pest-resistant insects. As farmers move forward with the objective of achieving greater crop
productivity it will be imperative to replace chemical inputs with safer alternatives to man‐
age insect pests in agricultural ecosystems. Within agricultural biotechnology, insect resist‐
ance is a prime research area that has potential to improve agricultural productivity and
provide much needed alternatives to pesticides while being effective against pests, innocu‐
ous to non-target organisms, and cost effective. With the advent of biotechnology, the ability
to genetically modify plants for insect resistance on a commercial scale is within reach. One
of the most extensively studied traits for insect resistance in soybeans involves the Bt gene.
Bacillus thuringiensis (Bt) is a common bacteria found in the environment. It has been used as
a biological control agent against lepidopteran insects for more than 50 years. Bt targets a
class of compounds responsible for insecticidal activity known as crystalline proteins, or cry
proteins (Cry1), that are highly toxic after ingestion. The mode of action for Cry1 toxins is
the disruption of midgut cellular membranes leading to cell death. One of the primary ad‐
vantages of using Bt genes for insect control in transgenic plants is the specific insecticidal
action toward insects from the Lepidoptera order leaving beneficial insects, birds, and mam‐
mals unharmed. Thus, the insertion of Bt toxins into plants, by genetic modification, is an
attractive model for the creation of insect resistant transgenic crops.
To date, many different plant species have been genetically modified to exhibit insect resist‐
ance using Bt. While the Bt trait has been commercialized in corn and cotton, it is still in de‐
velopmental stages in soybean. Transformation of soybean with Bt to induce resistance to
lepidopteron species has been performed for over a decade. By 1994 fertile transformed soy‐
beans containing a synthetic Bt (Cry1Ac) were generated [15, 16]. Stewart et al., used detach‐
ed leaf bioassays to show that transgenic soybean lines were resistant to multiple soybean
pests with less than 3% leaf defoliation compared to 20% observed in traditionally bred lepi‐
dopteron resistance soybean lines [16].
Other groups have used a similar strategy by evaluating soybeans engineered with Cry1Ac
for resistance to lepidopteron species under field conditions. One example compared Bt
lines to controls in the field using field cages and artificial infestation with lepidopteron lar‐
vae over a three year period [17]. In this case, Bt lines showed up to 9 times less defoliation
from pets when compared to control plants. Similarly, Mcpherson and MacRae reported the
evaluation of Bt soybean lines for suppression of lepidopteron species in the field over 2
years [18]. In this case, soybean plants expressing Cry1Ac were essentially absent of lepi‐
dopteron populations when compared to peak population densities of 20-30 larvae per row
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in control plots. Furthermore, Bt lines showed <1.5% defoliation when compared to 53% de‐
foliation in control plants.
The utility for Bt soybeans has become evident. This has lead to pyramiding strategies using
Cry1Ac with native plant resistance genes to increase plant resistance against insect-pests.
Several quantitative trait loci (QTLs) from soybean lines have been described as showing an‐
tixenosis and antibiosis resistance towards lepidopteron insects [19, 20]. This work lead to
the development of transgenic soybean lines by combining QTLs with synthetic Cry1Ac
[21]. In this case, field evaluations and detached leaf bioassays were used to test this multi‐
ple resistance gene pyramiding strategy for antibiosis resistance. Based on defoliation in the
field, as well as larval weight gain on detached leaves, soybean lines carrying a combination
of Cry1Ac and the QTL were significantly more resistant to lepidopteron pests.
While Bt soybean varieties have not been commercialized this body of research has lead
Monsanto to the development of soybeans that incorporate the Bt trait stacked with the sec‐
ond generation Roundup Ready germplasm [22]. Bt Roundup Ready 2 Yield seeds are cur‐
rently in Phase IV trials and are targeted for commercialization in Brazil in 2013. This
pyramiding strategy would be the first in-seed insect protection for soybeans and is expect‐
ed to offer an important technology for farmers who face significant yield loss due to insect
damage. Although not universal in its application and total in its protection, Bt will play a
central role in protecting the crop from major insect pests.
With the onset and success of Bt crops other avenues have been explored for their possible
roles in the development of transgenic insect resistant plants. These approaches include the
use of plant defense proteins, lectins, α-amylase inhibitors, insect chitinases, and defensins.
The development and implementation of engineered insecticidal soybean varieties is cur‐
rently in its infancy. The incorporation of a multiple gene stacking strategy will also be im‐
portant in the future development of insect resistant soybeans. Bt, in combination with other
biopesticides, has the potential to drastically reduce the consumption of chemical pesticides,
however it will be important to continue research and have a development strategy for a fu‐
ture generation of technology, to ensure that insects do not rapidly develop resistance.
3.3. Disease resistance
The United States, Brazil, and Argentina are the three major soybean-producing countries in
the world where more than 50% of all soybeans are harvested. Such a geographic distribu‐
tion facilitates the spread of insect-pests and diseases. Hence, soybean can be attacked by
many different pathogens, including bacteria, viruses, fungi, and nematodes. These patho‐
gens and pests can cause damage in seeds, roots, leaves, stems and pods, and usually are
tissue-specific. Therefore, disease resistance is another area of great interest for both re‐
searchers and farmers.
Disease control management is currently concentrated on agronomic practices, like planting
under tillage, use of lodging resistant varieties, wide row planting, and rotation with non-
host crops. Chemical control has poor efficiency because of low penetration and uneven dis‐
tribution due to an already formed canopy. In addition, chemical application can be
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extremely expensive for farmers and unhealthy for the environment. There has been little
success with conventional plant breeding for disease resistance in soybean leaving room for
other approaches such as the use of biotechnology to produce genetically modified soybeans
that have disease resistance.
3.3.1. Bacterial
Bacterial infections are widespread diseases that occur mainly in the mid-to-upper and
young leaves of the soybean plant. There are several bacteria which cause disease in soy‐
bean resulting in large amounts of yield loss and poor seed quality. While there has been
promising research in the development of bacterial disease resistance with the use of bio‐
technology in other crop plants such as rice, tomato, banana, and tobacco, there has been
less research on the development of bacterial disease resistance for soybean. This research
may lead to new strategies for the development of bacterial disease resistance in soybean.
3.3.2. Viral
The development of transgenic soybean that confers viral resistance has been studied a bit
more extensively. Viruses in soybean are global pests. Significant resistance to several virus‐
es in a number of plant species have been achieved through pathogen derived resistance by
the use of viral coat proteins which, when expressed in planta, can interfere with viral assem‐
bly. This is the same approach that has been used by several groups to develop transgenic
viral resistance in soybean. One of the first groups to investigate this approach was Di et al.,
who produced a soybean that was resistant to bean pod mottle virus (BPMV) [23]. This was
done by introducing a BPMV coat protein into the soybean genome. Transgenic events
showed complete resistance to BPMV infection. Another study created soybean lines that
were resistant to BPMV by inserting a BPMV capsid polyprotien. Events generated in this
case were subjected to infectivity assays and not only exhibited resistance to virus infection,
but also exhibited systemic infection, showing little to no visible symptoms [24]. Transgenic
lines such as these could lead to future commercial cultivars with resistance to BPMV.
The development of soybean mosaic virus (SMV) resistant soybeans is important since SMV
is found in all regions where soybean is grown and infection can cause yield loss up to 90%.
Despite progress in other important crop plants, efforts to produce transgenic soybeans re‐
sistant to SMV have advanced slowly. In order to produce soybean lines that could confer
pathogen derived resistance, plants were produced containing a coat protein gene and the 3'
UTR from SMV [25]. Coat protein gene transcripts were detected in transgenic lines and two
of the soybean lines were highly resistant to infections with the SMV virus. These results
represent the first example of stable genetically engineered SMV resistance in soybean.
The sense coat protein gene of soybean dwarf virus (SbDV) was used to acquire SbDV-re‐
sistant soybean plants [26]. These insertions were classified into two types: overexpression
of SbDV-CP mRNA, or repression accumulation of SbDV-CP mRNA, and siRNA by RNA
analysis prior to SbDV inoculation. In both cases, after infection with SbDV, most plants of
these transgenic lines remained symptomless, contained little SbDV-specific RNA and ex‐
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hibited SbDV-CP-specific siRNA. The possible mechanism of the achieved resistance was
thought to be RNA silencing. This same group later used RNA silencing to create resistance
for SbDV using inverted repeat-SbDV coat protein (CP) genes spaced by a β-glucuronidase
sequence [27]. Upon infection with virus, transgenic plants showed no symptoms of the dis‐
ease. Transgenic soybeans were shown to contain SbDV-CP-specific siRNA and little to no
SbDV-specific RNA, suggesting that resistance to SbDV was achieved by an RNA silencing-
mediated process.
3.3.3. Fungal
Fungi are the most common soybean pathogens and therefore represent targets for the de‐
velopment of disease resistant transgenic varieties in soybean. One of the more important
fungal diseases affecting soybeans grown in the United States and Brazil is Sclerotinia stem
rot (SSR) caused by the fungus Sclerotinia sclerotiorum (white mold). This mold has been as‐
sociated with the presence of oxalic acid (OA). Treatment of plants with OA induced symp‐
toms whereas metabolism of OA is correlated with fungal tolerance. Cunha et al., generated
transgenic soybean lines that overexpressed oxalate decarboxylase (OXDC) [28]. When
transgenic soybean lines were infected with white mold the disease progression showed sig‐
nificant reduction of severity that correlated with the level of transgene expression. Trans‐
genic events expressing high levels of OXDC showed complete resistance demonstrating the
feasibility of this approach.
Much of the research in the development of fungal disease resistance has focused on over‐
expression of a single gene to confer protection, though such a method favors co-evolution
and pathogenic resistance. An alternative strategy taken by Li et al., was to create multi-
gene resistance by overexpressing multiple anti-fungal genes [29]. Two such genes previ‐
ously  shown to  be  involved with  fungal  disease  resistance  are  chitinase  (CHI)  and the
barley ribosome-inactivating protein (RIP). While Li et al., successfully produced transgen‐
ic soybean overexpressing both traits, transgenic events were not challenged with fungal
infection.
An alternative technology has shown promise with controlling fungal infection through the
use of single-chain variable fragment (scFv) antibodies. While plants do not produce endog‐
enous antibodies, they can express and correctly assemble antibody fragments. In fact, anti‐
body production in soybean was first demonstrated in 1998 [30]. A similar antibody
approach was recently taken by Brar and Bhattacharyya to control Fusarium virguliforme
which is responsible for soybean sudden death syndrome (SDS) [31]. Using the pathogenic
toxin Tox1 as a target, soybeans were transformed with an antibody gene encoding scFv an‐
ti-FvTox1 to create transgenic lines with enhanced foliar SDS resistance compared to control
plants. Their results suggest that FvTox1 is a pathogenicity factor for the development of
SDS and that expression of a soybean plant scFv antibody can reduce a toxin-induced plant
disease. This biotechnology approach may be translational in fighting other plant diseases
that are induced by pathogenic toxins.
To date there are no commercially available transgenic soybeans that confer resistance to
disease, including fungal pathogens. In 2011 DuPont, Pioneer Hi-Bred, and Evogene an‐
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nounced a collaboration to develop soybean varieties displaying in-plant resistance to soy‐
bean rust [32]. This is a major step in the direction of creating the first commercially
available transgenic soybean variety that is resistant to a fungal pathogen.
3.3.4. Nematode
Plant parasitic nematodes are a significant agricultural problem causing major limitations on
crop yield and quality. It is estimated that plant parasitic nematodes cause approximately
$157 billion [USD] in damage worldwide. Current approaches used to combat agricultural
losses include the use of nematicides, cultivation techniques, and varieties with natural re‐
sistance. Nematicides include some of the most hazardous compounds used in agriculture
and alternative control is required due to health and environmental concerns over their use.
In soybean, the majority of yield loss can be attributed to infection by nematodes of the ge‐
nus Meloidogyne and Heterodera commonly referred to as root knot nematodes (RKN) and
soybean cyst nematodes (SCN), respectively. RKN and SCN infect plant roots and induce
the formation of specialized feeding sites. The establishment and maintenance of feeding
sites are crucial to the survival of nematodes making them an obvious target of interest for
novel control strategies. One approach that has emerged in recent years is the use of in plan‐
ta RNA interference (RNAi) to target genes of feeding nematodes. Through biotechnology,
plants can be engineered to produce dsRNAs that silence essential nematode genes. Inges‐
tion of plant-derived dsRNAs by the feeding nematode would trigger the RNAi process
thereby inactivating targeted genes and preventing or limiting nematode infection. There
are numerous genes known to be essential for nematode survival, and they have been the
subject of past reviews [33, 34]. Many of these appear to be candidates for use in an in planta
RNAi strategy to control nematode infection.
Steeves et al., was one of the first to demonstrate efficacy of an RNAi-based strategy to con‐
trol SCN [35]. Transgenic soybeans were generated following transformation with an RNAi
expression vector containing inverted repeats of a cDNA clone of the SCN major sperm pro‐
tein (MSP). RNA silencing was elicited in the cyst nematode following ingestion of dsRNA
molecules, and resulted in ~75% suppression of reproductive capabilities. Several years later
Li et al., used RNAi to test potential gene targets known to be involved with nematode re‐
production and fitness [36]. Soybean roots expressing small interfering RNAs against the
SCN genes Cpn-1, Y25, and Prp-17 showed a significant reduction in transcript levels in
nematode feeding sites. Furthermore, nematode suppression levels were similar to those ob‐
served with conventional resistance. Recently RNAi was used to disrupt genes involved
with RKN gall formation [37]. Genes encoding tyrosine phosphatase (TP) and mitochondrial
stress-70 protein precursor (MSP) were stably expressed in soybean roots, and following in‐
fection with RKN the number of galls was decreased by >90%. Nematode growth within
roots was measured and the diameter of nematodes inside transformed soybean roots was
reduced 5-fold over that of nematodes inside control roots.
Although there are a few cultivars of soybean that have natural resistance to some species of
nematode, there are currently no commercially available soybean varieties that offer geneti‐
cally modified resistance to nematodes. Over the past 10 years, there have been numerous
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candidate genes found within the nematode-plant interaction that hold potential for the de‐
velopment of novel genetically modified soybeans using an RNAi-based strategy. Results
from the above studies show the potential of RNAi technology for reducing gall formation,
limiting nematode reproduction and infection, and ultimately broadening soybean resist‐
ance to SCN and RKN. The production and eventual commercialization of nematode resist‐
ant soybean will benefit both producers and consumers by decreasing dependence on
hazardous nematacides and increasing overall soy grain yield.
4. Soybean trait enhancements
In 2008 Monsanto announced their Sustainable Yield Initiative - a pledge to double the
yields of corn, cotton, and soybeans by the year 2030 while simultaneously reducing aggre‐
gate key inputs such as water, land, and energy. While this will be an especially difficult
task given that the vast majority of high-quality farm land is already in use, several recent
reports involving transgenic soybean technologies support the notion that future biotechno‐
logical advances will indeed be able to help achieve such goals.
4.1. Crop yield
Crop yield is a highly complex trait, and increases in yield have previously been accom‐
plished through a variety of methods involving traditional breeding and modern biotech‐
nology. The introduction of transgenic crops in 1996 helped improve grain yield by
protecting plants from insects and disease pathogens that often result in yield pressure if not
treated. While new varieties of soybean combine the latest advances in both modern breed‐
ing with genetic modification technologies, there continues to be a search for gene-based ap‐
proaches with potential to increase soy grain yield. Preuss et al., recently performed a large-
scale screening for such yield increasing genes and reported that constitutive expression of
an Arabidopsis thaliana B-box domain gene (BBX32) resulted in plants with increased plant
height, node, flower, pod, and total seed number [38]. More importantly, field grown events
showed a 5-8% increase in plant height, 8-10% increase in pod number, and 11-14% increase
in total yield relative to control plants. It is believed that overexpression of AtBBX32 modu‐
lated circadian clock gene transcripts leading to an increase in the duration of reproductive
developmental stages (R3 through R7) of the seed which presumably accounted for the in‐
crease in seed yield. Over the next decades, it is likely that seed varieties containing these
and other yield traits will be commercialized.
4.2. Drought resistance
Drought is a major abiotic stress factor since it can greatly impact crop productivity and
grain  yield.  Soybeans  have  developed  several  adaptive  traits  to  endure  periods  of  dry
weather and drought.  Inclusion of these traits into quality germplasm continues to be a
major goal of traditional and marker-assisted breeding programs. While the genetic basis
of drought tolerance is not well  understood, researchers have focused on understanding
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physiological responses associated with drought (i. e. leaf wilting, water use efficiency, ni‐
trogen  fixation,  and  root  growth  biomass).  While  overexpression  of  single  downstream
gene targets have shown potential for increasing drought tolerance in Arabidopsis and to‐
bacco model systems, the majority of these findings have not yet been translated to major
crop species. One exception involves the overexpression of an endoplasmic reticulum-resi‐
dent molecular chaperone binding protein (BiP) which is believed to regulate Ca2+ signal‐
ing  responses.  Valente  et  al.,  showed  that  BiP-overexpressing  soybean  lines  exhibited
decreases in leaf wilting, leaf water potential, and stomatal closure under reduced and de‐
prived water  conditions  [39].  Furthermore,  transgenic  plants  showed decreased rates  of
photosynthesis  and  transpiration,  steady  levels  of  osmolytes  and  dry  root  weight,  de‐
creased induction of drought-associated mRNAs, and delayed leaf senescence relative to
control plants. While overexpression of BiP shows great potential as a target for increasing
drought resistance, it will be important to compare grain yields in field-grown transgenic
and control lines.
4.3. Increased oil content
Over the past decade, there has been a growing trend for industrial applications utilizing
soybean oil, and these applications compete with those used for edible consumption. One
example is the recent spike in soy-based biodiesel production which consumed just over 1
billion gallons of soybean oil  in 2011 compared with 5 million gallons in 2001 [40].  The
growing demand for soybean oil has sparked an interest in novel technologies that could
be used to increase the relative oil content of soybean seeds. The retooling of soybean me‐
tabolism to increase oil content is not a simple task given that the absolute levels of seed
oil  and seed protein seem to be set.  Increasing oil  content  comes at  the expense of  de‐
creasing protein content,  and vice versa.  To date,  only a few papers have reported suc‐
cesses in this area, and both involved manipulation of enzymes and substrate pools in the
Kennedy pathway which is responsible for the production of triacylglycerols (TAGs) - the
major component of soybean seed oil. In 2008, Lardizabel et al., overexpressed fungal di‐
acylglycerolactetyltransferase (DGAT2) in soybean seeds [41]. DGAT2 converts diacylgly‐
cerols  (DAGs)  to  TAGs.  Transgenic  soybeans  overexpressing DGAT2 were  grown at  63
locations within the United States and Argentina over five growing seasons, and showed
a 1.5% increase  in  total  seed oil  with  no  reduction of  seed protein  content  or  yield.  In
2009, Rao and Hildebrand overexpressed the yeast sphingolipid compensation (SLC1) pro‐
tein in soybean seeds [42]. SLC1 has been shown to have lysophosphatidic acid acyltrans‐
ferase  (LPAT) activity  which plays  a  role  in  the  conversion of  lysophosphatidic  acid to
phosphatidic  acid,  the  precursor  to  DAG  in  the  Kennedy  pathway.  Overexpression  of
yeast SLC1 resulted in soybean somatic embryos with 3. 2% increased oil content and sta‐
ble  transgenic  lines  with  1.5% increased oil  content  in  seeds.  Given current  commodity
pricing for soybean oil [43], a 1.5% increase in oil adds ~$1.2 billion [USD] in value to the
United States  soybean crop alone.  As soybean oil  prices  rise  it  is  anticipated that  other
metabolic engineering strategies will be developed and used to obtain similar increases in
seed oil content.
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5. Health and nutrition
Soybean is considered a dual use crop since it is a valuable source of seed protein and seed
oil. Due to consumer health awareness and an increased demand for vegetable oil, much at‐
tention has been drawn to seed oil quality and content. To address these needs, efforts have
been made with soybean to increase oxidative stability of soybean oil, enhance fatty acid
content of oil, and increase total oil content within the seed. Significant progress has been
made by breeders to improve overall yield of soybean, however minimal advancements
have been made in the development of high-yield germ lines that have a major shift in car‐
bon flux for increased total protein or oil content in the seed. This may be attributed to the
inverse correlation between absolute oil and protein contents within soybean seeds. Biotech‐
nology offers new tools for the development of soybeans that have improved oil quality for
use in food, feed, and industrial applications. These nutritional enhancements have been
achieved by directed modification of fatty acid biosynthesis to alter amounts of fatty acids
that naturally occur in soybean, or to produce novel fatty acids. Two fatty acid profiles that
have been targeted through genetic strategies include soybeans with low linolenic acid oil
content and high oleic acid oil content.
5.1. Fatty acid content
Linolenic acid (LA) accounts for 10-13% of the total fatty acid content of soybean oil. This
fatty acid reduces oxidative stability of oil which results in rancidity and decreased shelf-
life. A family of three desaturase genes (GmFAD3) contribute to LA biosynthesis in soybean.
Flores et al., employed a targeted gene silencing approach to suppress the GmFAD3 gene
family using a single RNAi construct [44]. The down regulation of this gene family resulted
in low linolenic soybeans with LA contents below 2%. Oleic acid (OA) is a pre-cursor of LA
and is considered a healthy source of fat. Conventional soybean oil contains ~18% OA.
While high oleic soybean oil has obvious nutritional value, conventional breeding of high
oleic soybean lines have not materialized, in part due to the decrease of yield and environ‐
mental instability associated with bred traits. The observed yield drag may be attributed to
an alteration in the fatty acid profiles within vegetative tissues of soybean. Progress toward
decreasing this yield drag has been made by down regulating Δ12 desaturases (FAD2-1A
and -1B) which converts OA to LA [45, 46]. Seeds resulting from this genetic approach have
an increased OA content to ~80% without alterations of vegetative tissue fatty acid contents.
In combination with high levels of OA, elevated steric acid levels in soybean oil is also desir‐
able to meet needs of confectionary applications, and development of such soybeans may be
possible in the future using similar approaches.
Nutritional enhancements such as increased ω-3 fatty acid levels are also desired for hu‐
man food and animal feed consumption. Two fatty acids, γ-linolenic acid (GLA) and stear‐
idonic acid (SDA) are of particular interest since they exhibit pharmacological properties
and nutritional value, respectively. Sato et al.,  were successful at increasing these impor‐
tant fatty acids in soybeans by overexpressing a borage Δ6desaturase which converts LA
and α-linolenic (ALA) to GLA and SDA, respectively [47].  Field studies with transgenic
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soybean harboring the borage Δ6desaturase produced GLA to ~27% and SDA to ~3% in
seed oil [48]. To increase SDA levels in soy, Eckert et al., pyramided the borage Δ6desatur‐
ase with an Arabidopsis Δ15desaturase which converts LA to ALA [49]. It was reasoned that
increased pools of ALA would lead to increased levels of SDA via the Δ6desaturase. This
strategy resulted in soybean lines with 21.6% SDA when grown under greenhouse condi‐
tions. SDA in turn is a precursor for the long chain polyunsaturated fatty acids eicosapen‐
taenoic  acid (EPA) and docosahexaenoic  acid (DHA).  Diets  rich in  these  fatty  acids  are
associated with cardiovascular fitness. While humans and animals possess the enzymatic
machinery to convert SDA to EPA and DHA, diets are often supplemented with EPA and
DHA derived from fish oil since vascular plants lack the genes for synthesis of these fatty
acids. Attempts have been made to assemble these pathways in soybean by using biosyn‐
thetic genes from fungi, algae, and protists along with seed specific co-expression of these
genes [50]. In such experiments EPA levels approached 20% and DHA levels represented
up to 3% of total seed fatty acid content in soybean. The production of such important fat‐
ty acids has significant market potential, particularly with respect to human, poultry, pet,
and aquaculture feed applications.
5.2. Tocopherols
Tocopherols are lipid-soluble antioxidants that are extracted during the commercial process‐
ing of soybean seeds and add to the stability of the oil. In soybean there are four forms of
tocopherols (α, β, γ and δ,) classified by the number of methyl groups present on the mole‐
cule. These molecules are collectively referred to as vitamin E, with δ - and γ -tocopherols
being the most predominant forms in seeds. Biotechnological enhancements of tocopherols
in soybean have mainly focused on increasing the amounts of α-tocopherol since this form
has the highest nutritional value. Attempts to increase total levels of tocopherols have only
been marginally successful. Examples of studies to increase total levels have focused on up-
regulating homogentisatephytyltransferase (HPT) activity in seeds. While HPT catalyzes the
first step in tocopherol synthesis, overexpressing lines resulted in little increase of tocopher‐
ol in transgenic seeds [51, 52]. A modest increase in tocopherol content was achieved by the
expression of corresponding HPT genes from Arabidopsis and Synechocystis with a strong
seed specific promoter [52]. This approach resulted in a 1.5-fold increase of total tocopherol
content. This same group also expressed a bacterial chorismatemutase-prephenate dehydro‐
genase (TYRA) gene with several other enzymes under the control of seed specific promot‐
ers and observed a >10- fold increase in total vitamin E type molecules.
To generate soybean lines with increased levels of tocopherols a more direct approach has
involved overexpression of homogentisategeranylgeranlytransferase (HGGT), an enzyme
involved in the biosynthesis of tocopherols in monocots. Recently transgenic expression of
rice HGGT was expressed in soybean with a seed-specific and constitutive promoter [53].
Transgenic soybean expressing the HGGT gene had significantly higher levels of antioxi‐
dant activities and showed enhanced vitamin E levels associated with the presence of all
forms of tocopherols, including tocotrienols (with the exception of the β- form) which are
not found naturally in soybean.
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Enhanced amounts of α-tocopherol in soybean have proven easier to metabolically engineer.
Expression of genes for two enzymes responsible for methylation of tocopherol head groups
(VTE3 and VTE4) from Arabidopsis were co-expressed within the seed and generated plants
with α-tocopherol levels greater than 90% of total tocopherol content [54]. The total levels of
tocopherol remained the same in these seeds, showing a shift in tocopherol to mainly the α-
form yielding a 5-fold increase in vitamin E activity. This research can lead to soybean oil
with enhanced vitamin E and more nutritional value for consumers.
5.3. Dietary amino acids
Soy is also deficient in several essential dietary amino acids, most notably methionine and
cysteine due to their high sulfur contents. Albumins from Brazil nuts, sunflowers, and corn
have been expressed in soybean and although they resulted in increased methionine and
cysteine levels, they are not adequate enough to avoid supplementation of these amino acids
in animal feed and human diets. The physical synthesis of cysteine is carried out by the en‐
zyme O-acetylserinesulfhydrylase (OASS). In an attempt to increase sulfur containing amino
acids in soybean, Kim et al., overexpressed cytosolic OASS and found that transgenic seeds
contained elevated levels of both protein bound cysteine (58-74%) and free cysteine (22-32%)
[55]. Another approach used to increase sulfur amino acid content in soybean is the use of a
maize zein gene which gives rise to several species of insoluble proteins containing high lev‐
els of methionine. Dinkins et al., overexpressed maize zein in soybean seeds and observed a
12-20% increase in methionine and 15-35% increase in cysteine without adverse effects on
protein composition [56].
The essential amino acids lysine and threonine have also been explored for their potential to
create nutritionally enhanced soybean. An increased level of lysine was observed by geneti‐
cally engineering the lysine biosynthetic pathway to circumvent the normal feedback regu‐
lation of the enzymes aspartokinase and dihydrodipicolinic acid synthase in soybean [57]. In
this case, a >100-fold increase of free lysine and 5-fold increase of total seed lysine content
was observed. More recently, soybeans showing enhanced threonine levels have been engi‐
neered using seed-specific expression of lysine-insensitive variants of aspartate kinases from
bacteria [58]. This strategy produced transgenic soybeans with a 100-fold increase in threo‐
nine levels and 3.5-fold increase in total free amino acid content without negative impacts
on seed morphology or germination. While enhancement of essential amino acids in soy‐
bean seeds has clear potential for commercial applications, it will be important to demon‐
strate that transgenic soybean with increased nutritional enhancement traits also maintain
optimal agronomic characteristics when grown in the field under a variety of conditions.
6. Soybeans as bioreactors for pharmaceuticals
Recombinant proteins are widely used in medicine, research laboratories, food and nutri‐
tion, and play a key role in important agriculture and biopharmaceutical industries. Since
the development of recombinant DNA technology in the early 1970’s, the commercial pro‐
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duction of recombinant proteins has traditionally relied on a variety of protein expression
systems, each with intrinsic advantages and disadvantages. Over the years several methods
have been used to produce recombinant proteins. Traditionally, prokaryotic systems based
on fermentation have been used for the production of biopharmaceuticals and enzymes. The
bacteria Escherichia coli, being one of the earliest and most widely used host for this method,
has been used in the production of human insulin since the 1970’s [59]. Other platforms in‐
clude the use of fungal cells and yeast, which have been used as an expression system that is
able to perform many of the post-translational modifications required by recombinant pro‐
tein production. Recombinant proteins that require more complex modifications can be pro‐
duced using insect or mammalian cells, or transgenic animals. However, major
disadvantages associated with these platforms include the inability to perform complex
post-translational modifications, the alteration in glycosylation patterns affecting protein ac‐
tivity, the high overall cost associated with manufacturing, the potential for contamination,
and long time commitments associated with production in transgenic animals making these
platforms impractical for the production of most proteins.
Over the past two decades, there has been a push for recombinant protein technologies to
move towards more effective expression systems. These systems must be safe, cost-effective,
and conducive to post-translational modifications and processing methods on a large scale.
Transgenic plants represent an economical system for accurate expression of complex re‐
combinant proteins on a large scale. Plant cells combine the potential for full post transla‐
tional modifications and correct protein folding with simple growth requirements. The use
of plants as a platform for recombinant protein production has a low risk of contamination
with prions, viruses, and other pathogens that infect mammalian cells, and therefore offer
advantages that are not associated with existing expression systems. An important advant‐
age of plants as a bioreactor is that recombinant proteins and biopharmaceuticals may be ex‐
pressed in multiple plant organs including seeds which naturally accumulate high amounts
of stored proteins. In general, crops that have higher protein content are more cost-effective
for molecular farming. Among recombinant systems that utilize seeds, soybeans present an
exceptionally high endogenous protein content, which can reach up to 40% of the dry seed
weight. Soybeans are an ideal source of protein for food and feed thus occupying a unique
position as a premier target for genetic engineering, and as a platform for the production of
recombinant protein. An important characteristic favoring expression in soybean seeds is
that these organs have evolved as specialized compartments to store proteins for embryo
nutrition. Based on this, soybean seeds offer an environment with metabolic adaptations
that permit the stable and long-term storage of proteins, reducing the requirement for so‐
phisticated and expensive conditions for storage. This makes it possible to stockpile harvest‐
ed seeds so that the downstream processing can be made available based on the demands of
the industry. Similarly, soybean seeds provide a compact compartmentalization biomass,
which can considerably reduce overall production costs since purification expenses are typi‐
cally inversely proportional to the final concentration in the plant biomass.
The concept of a soy-derived pharmaceutical was tested back in 1995 when Cho et al., devel‐
oped a transformation expression cassette using a soybean seed-specific lectin promoter to
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test for potential expression of the β-glucuronidase reporter gene [60]. This same expression
cassette was used to produce bovine β-casein in soybean which accumulated to 0.1-0.4% of
seed total soluble protein (TSP) [61]. A follow-up paper characterized post-translational
processing, subcellular localization to the PSV, and purification of transgenic β-casein [62].
These proof-of-concept studies showed that a seed-specific promoter could be used to target
stable expression of proteins with commercial value in soybean seed.
6.1. Antibodies
Monoclonal antibodies (mAbs) have played a major role in the advancement of biotechnolo‐
gy and development of mAb-based therapeutics and diagnostics. Plants have great potential
to serve as a platform for the production of antibodies for therapeutic use. One of the first
reports of a functional plant-based antibody was developed in soybean. In an effort to ex‐
plore cost effective methods of mucosal immunoprotection against sexually transmitted dis‐
eases, Zeitlin et al., expressed a humanized monoclonal anti-herpes simplex virus 2 (HSV-2)
antibody in leaf tissue [63]. That study compared purified soy-derived and mammalian cell-
derived HSV-2 mAbs and found that both were similar with respect to stability in human
semen and cervical mucus over a 24 hour period. Both antibodies were also able to diffuse
in human cervical mucus, and were efficacious in preventing vaginal HSV-2 infection in a
murine model.
6.2. Vaccines
When plants are mentioned as a platform for the production of pharmaceuticals, the concept
of edible vaccines often comes to mind. Edible vaccines are desirable since they would elimi‐
nate the use of needles and specialized personnel to administer shots, which may have
broad applicability in developing nations. Soybean seeds represent an ideal target for the
production of vaccines since soymilk-based formulations are safe and can be easily adminis‐
tered orally. Furthermore, soybean seeds are capable of storing vaccine antigens for many
years at ambient temperatures without loss or degradation of the antigen [64-66]. Such fea‐
tures can reduce the need for a cold chain therefore reducing costs.
Vaccines that can be administered at mucosal surfaces offer systemic immunity. Subunit an‐
tigens used to vaccinate orally or nasally are often ineffective and require formulation with a
mucosal adjuvant for increased efficacy. The heat labile toxin (LT) of E. coli is comprised of a
single A subunit (LTA) and pentameric B subunit (LTB) and has been shown to act as both a
strong mucosal adjuvant as well as an antigen [67]. Moravec et al., targeted LTB expression
to the endoplasmic reticulum of seed storage parenchyma cells where it accumulated to lev‐
els up to 2.4% of seed TSP [68]. Mice orally immunized with seed extracts containing LTB
induced both, systemic IgG and mucosal IgA anti-LTB antibody responses. The soybean de‐
rived LTB also increased an antibody response against a co-administered bacterial FimHt
antigen by 500-fold demonstrating that soy-derived LTB may function as an oral adjuvant.
Several subunit antigens have been expressed in soybeans that are important to the agricul‐
tural industry and could lead to effective vaccines. FanC is a specialized adhesion protein
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located on the bacterial surfaces of Enterotoxigenic E. coli (ETEC). K99 and other ETEC
strains cause acute diarrhea in humans and livestock and can be severe and even cause
death if left untreated. ETEC vaccinations are routinely administered parenterally to preg‐
nant farm animals in order to stimulate systemic immunity and offer protection in new‐
borns. An edible form of this vaccine has the potential to increase efficacy by conferring
mucosal immunity at sites of pathogen invasion. Piller et al., constitutively overexpressed
the bacterial FanC antigen in soybeans and reported stable accumulation to levels represent‐
ing ~0.4% TSP in both leaves and seeds [69]. Mice immunized with adjuvanted soymilk for‐
mulations containing FanC elicited FanC-specific systemic and cellular immune responses
demonstrating immunogenicity of the soy-derived antigen.
In another study a soybean-based vaccine was developed against the virus that causes por‐
cine reproductive and respiratory syndrome (PRRS) [70]. PRRS is a serious health problem
among breeding swine herds and the current vaccine is not efficacious when applied in the
field. Vimolmangkang et al., overexpressed a nucleocapsid protein (PRRSV-ORF7) that ac‐
cumuolated to 0. 64% of seed TSP. Intragastric immunization of mice with transgenic seed
extract, in the absence of adjuvant, induced specific humoral and mucosal immune respons‐
es against PRRSV-ORF7 [70].
6.3. Therapeutics
Protein therapeutic use is limited by the shortfalls in manufacturing capacity and the high
cost of production. While an aging population is a key driver of the protein therapeutics
market, the potential for future growth is dependent largely on the industry overcoming
drug delivery challenges and cost issues. Plants are cost-effective systems that excel at pro‐
ducing complex therapeutic proteins and therefore could help address some of these issues.
The high protein content of soybean seeds, low costs associated with growth, simplified pu‐
rification methods, and safety, make soybean a unique platform for the production of pro‐
tein-based therapeutics.
Russell et al., expressed human growth hormone (hGH) in soybean with transformation cas‐
settes using both the constitutive 35S promoter as well as a soybean seed-specific promoter
7S β-conglycyinin [71]. The resulting expression of hGH, both constitutively and within the
seed, was detected at low levels of 0.0008% TSP. More recently hGH was expressed in soy‐
bean seeds with a more effective expression cassette utilizing the 7S α’ subunit of β-congly‐
cinin promoter and α-coixin signal peptide. In this case, hGH was directed to protein
storage vacuoles within the seed and accumulated to 2.9% TSP. Bioassays demonstrated that
the soy-derived hGH was fully active [66]. The cost of recombinant E. coli-derived hGH is
still a very expensive therapy. Having such a high level of bioactive hGH protein expression
in soybean seeds demonstrates the potential for high-yield production of recombinant pro‐
teins in soybean seeds and could lead to reduce costs for large-scale production of therapeu‐
tic molecules.
Human basic fibroblast growth factor (bFGF) is another high value therapeutic that has been
expressed in soybean seeds [72]. This therapeutic was expressed under the control of the
soybean seed specific G1 promoter and endogenous signal sequence from soybean. The
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bFGF protein accumulated to levels of ~2.3% of seed TSP and biological activity of the trans‐
genic protein was confirmed by its mitogenic activity in mice.
Recombinant expression of Insulin was first reported using E. coli [59] and has since been
commercialized. Like many pharmaceuticals derived from other expression systems, the po‐
tential for contamination along with high costs associated with production remain consider‐
able for this hormone. To show that a soybean expression system could address some of
these issues Cunha et al., used a sorghum γ-kafirin seed storage protein promoter and α-
coixin PSV signal peptide to target recombinant proinsulin expression to soybean seeds [65].
Transgenic protein was stably expressed in seeds though accumulation levels were not re‐
ported. Transgenic seeds containing proinsulin were stable for up to seven years when stor‐
ed under ambient storage conditions.
The soybean platform has also been used to produce a therapeutic for reducing systolic
blood pressure. Novokinin is a hypotensive peptide that has vasorelaxing activity [73]. No‐
vakinin was expressed in soybean seeds under the control of a modified β-conglycinin pro‐
moter and accumulated to 0.5% of seed TSP. A purified soy-derived formulation, as well as
a less pure defatted flour formulation, was orally administered to groups of spontaneously
hypertensive rats. Both the purified and partially purified formulations successfully reduced
systolic blood pressure after a single dose [74].
Haemophilia B is a bleeding disorder that results from a deficiency of human coagulation
factor IX (hFIX). The current treatment for this disease is intravenous infusion of plasma-de‐
rived or recombinant hFIX protein. While this treatment is effective at preventing and ar‐
resting hemorrhage, it is very costly and the protein is difficult to produce in large
quantities. Using a biolistic transformation approach, hFIX expression was targeted to soy‐
bean seeds using the soy 7S promoter and coixin signal peptide [75]. Recombinant hFIX pro‐
tein accumulated to 0.23% of seed TSP, and purified protein exhibited blood-clotting activity
up to 1. 4% of normal plasma demonstrating functionality and efficacy of the soy-derived
protein. The recombinant protein was stable for 6 years when stored at room temperature.
Soybeans are also capable of supporting expression and stable accumulation of large and
complex proteins that can be difficult or impossible to express using current expression sys‐
tems. Human thyroglobulin (hTG) is a 660 kDa homodimeric protein that is used as a pro‐
tein standard and diagnostic for the detection of thyroid disease. To date, no expression
system has been capable of producing a recombinant form of hTG which is likely due to
strict requirements for correct post-translational modification and proper folding during
protein synthesis. As a result, commercial hTG supplied to manufacturers for their assay
kits is derived from cadaver and surgically removed thyroid tissue. The heterogeneity and
lack of uniformity of commercially-purified hTG preparations is a major factor of variation
between kits of different manufacturers. To explore the potential of soybean as a platform
for production of large and complex proteins, Powell et al., used the 7S promoter and en‐
dogenous hTG signal peptide to target recombinant expression of hTG to soybean seeds
[76]. Transgenic lines showed stable expression of full length hTG dimeric protein over mul‐
tiple generations, and accumulated the protein to levels approaching 1.5% of seed TSP.
Functionality of soy-derived hTG was demonstrated with commercial ELISA kits developed
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specifically for the detection of hTG in patient sera. The expression of 660 kDa dimerich TG
appears to be the largest functional recombinant protein expressed in any plant system to
date, and demonstrates the practicality of soy as an alternative system for the expression of
proteins that are recalcitrant to expression in traditional systems [76].
Soybeans have a high intrinsic capacity for protein production and storage. Other than vari‐
ability caused by nutrient modulation or environmental effects, the relative distribution of
seed protein is primarily determined by genetics. Several groups have been able to achieve
recombinant protein expression in soybean seeds at respectable levels (approaching 3% of
seed TSP). However, knowledge of protein distribution in soybeans may help to further
maximize expression levels. Schmidt and Herman tested this theory by overexpressing
Green Fluorescent Protein (GFP) in soybeans with a β-conglycinin suppression background,
to observe whether proteome rebalancing would result in a higher GFP yield [77]. They
found that the rebalancing of intrinsic proteins could be exploited to obtain protein yields
which increased ~4-fold in suppression backgrounds and approached levels representing
>7% seed TSP. Thus, proteome rebalancing may represent a strategy that can be used to de‐
velop soybean lines capable of producing high levels of recombinant proteins in the future.
7. Conclusion
Over the past 25 years, soybean production in the United States has grown by nearly 57%
while during that same period the number of acres used to grow soybeans has increased by
only 24%. It is predicted that the worldwide requirement for grain will rise by 40-70% by the
year 2050, driven in large part by the growing world population and the increase in demand
for protein-rich diets. Clearly the demand for soybean protein and soybean oil is outpacing
grain production, which in turn is outpacing available land for growing soybeans. Over the
next 50 years, farmers will need to produce as much food as they did in the previous 10,000
years combined, and with fewer resources. The identification of various agricultural im‐
provements such as herbicide, insect, and disease resistance which will allow farmers to ob‐
tain increased yields with reduced environmental inputs will be crucial. Traits that not only
increase grain yield, but also improve the absolute levels of soy protein and soy oil within
the seed will also be important for producers and consumers worldwide. While soybean is
recognized for its high protein content, it is also the most widely grown oil-seed crop in the
United States. Enhancing nutritional value of soybean oil will greatly increase the effective‐
ness and value of soy as a food crop, help meet the needs of a growing population, and im‐
prove human health.
Over the past decade, soybean has emerged as an ideal expression platform with potential
to address current healthcare needs. These unmet needs include cost-effective alternatives to
existing protein-based therapeutics, simplified methods for the administration of therapeu‐
tics, and the development of reagents that could lead to better diagnostic assays and novel
medical devices. Soybeans are unique with respect to protein expression platforms. They are
safe to consume, cost-effective to grow, rich in protein content, and stable for years under
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ambient storage conditions. They have been engineered to express a variety of potential
therapeutics, including mAbs, vaccine antigens and adjuvants, hormones, growth factors,
and blood-clotting factors. Seed-based expression of 660 kDa homodimerich TG underscores
the potential of the soybean system to produce large and complex proteins that cannot be
produced in yeast, insect, and mammalian cell cultures. The efficacy of engineered thera‐
peutics in crude soymilk formulations could lead to oral vaccines and therapies that require
little, if any, purification from other seed proteins. Reports demonstrating long-term stabili‐
ty of seed-derived therapeutics in the absence of climate control directly address cold chain
issues associated with vaccines and other therapeutics. With seed protein levels of ~40% and
transgene expression levels approaching 3% of TSP, a single soybean plant yielding 300
seeds can produce >500 mgs of transgenic protein. To put this in perspective, a single soy‐
bean plant can produce 500 doses of a vaccine antigen administered at 1 mg/ml, or alterna‐
tively, $50,000 [USD] of a therapeutic valued at $100/mg [USD].
The use of soybean as a platform for the production of therapeutics represents a technology
with the potential to revolutionize our current approaches to healthcare. Harnessing the full
potential of the soybean platform will depend on further increasing stable transgene expres‐
sion levels, developing efficient purification methods, obtaining interest from pharmaceuti‐
cal partners, and overcoming issues associated with commercialization. The production of
vaccines, antibodies, and other therapeutic proteins will undoubtedly continue to develop
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